Valeant CEO says drug pricing may drop
The CEO of Valeant Pharmaceuticals, which is being investigated by the government for raising drug prices, predicted more modest price increases ahead for the pharmaceutical industry. The prices on...
View ArticleFour legislative issues managed care pharmacists should watch
The Academy of Managed Care Pharmacy (AMCP) is currently tracking about 60 bills in this legislative session that could affect managed care pharmacy. That's according to Reginia Grayson Benjamin, BS,...
View ArticleThe last word Congress is final hurdle in removing EHR ‘gag clauses’
Congress will likely move to forbid non-disclosure clauses, also known as “gag clauses,” in electronic health record (EHR) contracts with healthcare providers, but final action won’t occur until 2016...
View ArticleHepatitis C drugs come under fire again
A new US Congressional report about the price of hepatitis C drug Sovaldi, along with a new class action lawsuit against Blue Cross Blue Shield involving Harvoni coverage, are the latest in a series...
View ArticleThe last word: Will 21st Century Cures Act harm patient safety?
The 21st Century Cures Act, which the U.S. House of Representatives passed in July, isn’t likely to emerge from the full Congress in its present form. The Senate will have its say first and so action...
View Article
